NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 25 04:00PM ET
197.14
Dollar change
+0.64
Percentage change
0.33
%
IndexS&P 500 P/E38.22 EPS (ttm)5.16 Insider Own9.35% Shs Outstand715.60M Perf Week5.52%
Market Cap141.09B Forward P/E23.01 EPS next Y8.57 Insider Trans-0.06% Shs Float648.74M Perf Month-6.31%
Income3.77B PEG4.64 EPS next Q1.65 Inst Own81.34% Short Float0.93% Perf Quarter-19.80%
Sales23.82B P/S5.92 EPS this Y2.88% Inst Trans0.05% Short Ratio1.22 Perf Half Y-24.55%
Book/sh71.06 P/B2.77 EPS next Y11.31% ROA4.63% Short Interest6.03M Perf Year-22.11%
Cash/sh2.78 P/C70.79 EPS next 5Y8.23% ROE7.22% 52W Range171.00 - 281.70 Perf YTD-14.12%
Dividend Est.1.22 (0.62%) P/FCF28.78 EPS past 5Y9.03% ROI5.63% 52W High-30.02% Beta0.81
Dividend TTM1.13 (0.57%) Quick Ratio1.05 Sales past 5Y7.33% Gross Margin59.80% 52W Low15.29% ATR (14)8.18
Dividend Ex-DateMar 28, 2025 Current Ratio1.43 EPS Y/Y TTM-12.75% Oper. Margin21.67% RSI (14)51.02 Volatility2.98% 4.64%
Employees63000 Debt/Eq0.35 Sales Y/Y TTM-9.19% Profit Margin15.81% Recom1.37 Target Price244.78
Option/ShortYes / Yes LT Debt/Eq0.31 EPS Q/Q-8.94% Payout20.42% Rel Volume0.53 Prev Close196.50
Sales Surprise3.04% EPS Surprise15.52% Sales Q/Q-0.95% EarningsApr 22 BMO Avg Volume4.96M Price197.14
SMA202.68% SMA50-2.45% SMA200-17.43% Trades Volume2,608,658 Change0.33%
Date Action Analyst Rating Change Price Target Change
Apr-10-25Upgrade Barclays Equal Weight → Overweight $205
Mar-21-25Upgrade Goldman Neutral → Buy $260
Mar-14-25Upgrade Stifel Hold → Buy $260
Feb-03-25Downgrade Raymond James Outperform → Mkt Perform
Dec-23-24Initiated Scotiabank Sector Perform
Dec-19-24Initiated Guggenheim Buy $275
Dec-13-24Upgrade BofA Securities Neutral → Buy $290
Oct-31-24Upgrade Wolfe Research Peer Perform → Outperform $285
Oct-01-24Initiated Stephens Overweight $315
Aug-28-24Initiated Wells Fargo Equal Weight $280
Apr-24-25 04:54AM
Apr-23-25 05:30PM
12:10PM
11:40AM
03:01AM
10:30PM Loading…
Apr-22-25 10:30PM
09:35PM
09:35PM
04:05PM
02:22PM
12:14PM
11:09AM
10:00AM
09:30AM
09:28AM
09:28AM Loading…
09:28AM
07:10AM
06:17AM
06:07AM
06:00AM
Apr-21-25 10:16AM
08:04AM
Apr-19-25 01:25AM
Apr-16-25 09:15AM
Apr-15-25 01:49PM
10:00AM
Apr-13-25 05:41PM
Apr-11-25 08:28AM
03:20AM
Apr-10-25 01:30PM
11:44AM Loading…
11:44AM
Apr-08-25 02:22PM
Apr-07-25 07:28PM
12:50PM
Apr-04-25 09:06PM
11:57AM
09:25AM
Apr-03-25 07:51AM
Apr-02-25 07:30AM
12:10AM
Apr-01-25 04:59PM
04:55PM
Mar-31-25 10:24PM
04:35AM
02:27AM
Mar-30-25 11:19PM
09:05AM
Mar-29-25 04:26PM
Mar-28-25 10:05AM
Mar-27-25 10:40AM
06:45AM
Mar-24-25 05:06PM
02:15PM
Mar-22-25 06:59PM
08:00AM
12:31AM
Mar-21-25 05:40AM
Mar-20-25 04:15PM
02:05PM
01:26PM
09:05AM
Mar-15-25 09:40AM
Mar-14-25 04:20PM
Mar-13-25 08:01AM
Mar-12-25 08:29AM
Mar-11-25 05:02AM
Mar-10-25 08:30AM
Mar-07-25 11:43AM
Mar-04-25 04:02AM
Feb-28-25 11:30AM
Feb-27-25 09:11AM
Feb-25-25 04:15PM
01:49PM
Feb-24-25 08:06AM
Feb-23-25 08:50AM
Feb-20-25 04:45PM
04:15PM
Feb-12-25 11:34AM
11:17AM
09:21AM
Feb-09-25 04:26PM
Feb-08-25 03:17PM
Feb-07-25 09:50AM
Feb-05-25 11:22AM
Feb-03-25 12:47PM
11:33AM
Feb-01-25 03:44AM
Jan-31-25 04:47PM
01:11PM
07:31AM
02:15AM
Jan-30-25 06:59AM
12:14AM
Jan-29-25 03:37PM
12:18PM
11:00AM
10:20AM
08:56AM
07:10AM
06:56AM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glenstone FoundationSee RemarksApr 24 '25Proposed Sale196.50598,281117,562,216Apr 24 05:28 PM
King WilliamFormer OfficerMar 11 '25Proposed Sale207.1464,69713,401,340Mar 11 04:03 PM
King WilliamOfficerFeb 21 '25Proposed Sale209.97114,35124,010,531Feb 21 04:18 PM
Sabeti Pardis Cformer Board of DirectorsFeb 18 '25Proposed Sale204.284,337885,953Feb 18 01:04 PM
SPOON ALAN GDirectorFeb 07 '25Option Exercise59.343,928233,088121,068Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Sale206.46550113,553120,518Feb 10 05:00 PM
SPOON ALAN GDirectorFeb 07 '25Proposed Sale206.46550113,553Feb 07 03:34 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Option Exercise58.595,700333,96325,930Jan 31 05:00 PM
Ellis Brian WSenior Vice President - GCJan 30 '25Sale224.135,7001,277,54120,230Jan 31 05:00 PM
Ellis Brian WOfficerJan 30 '25Proposed Sale224.135,7001,277,542Jan 30 12:56 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Option Exercise58.5926,3181,541,97241,543Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 26 '24Sale236.5926,3186,226,49715,225Nov 27 05:01 PM
Raskas DanielSVP - Corporate DevelopmentNov 25 '24Sale238.008,3701,992,06015,225Nov 27 05:01 PM
Raskas DanielOfficerNov 26 '24Proposed Sale236.5926,3186,226,496Nov 26 04:40 PM
Raskas DanielOfficerNov 25 '24Proposed Sale238.008,3701,992,060Nov 25 12:04 PM
Glenstone FoundationSee RemarksNov 05 '24Proposed Sale247.76100,00024,776,000Nov 05 04:01 PM
Weidemanis JoakimFormer DirectorOct 23 '24Proposed Sale254.9517,6594,502,216Oct 23 01:10 PM
Couchara GeorgeannSVP, Human ResourcesAug 26 '24Sale268.37952255,4834,212Aug 27 05:04 PM
Couchara GeorgeannOfficerAug 26 '24Proposed Sale268.37952255,483Aug 26 04:40 PM
Glenstone FoundationSee RemarksAug 13 '24Proposed Sale267.2047,93712,808,766Aug 13 04:05 PM
Blair RainerPresident & CEOJul 31 '24Sale280.009,0072,521,96097,983Aug 02 05:00 PM
FILLER LINDADirectorAug 01 '24Option Exercise59.343,928233,08845,077Aug 02 05:00 PM
FILLER LINDADirectorAug 01 '24Sale279.503,9281,097,87641,149Aug 02 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerAug 01 '24Option Exercise62.8516,1721,016,41045,579Aug 02 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerAug 01 '24Sale279.8416,1724,525,55529,407Aug 02 05:00 PM
McGrew MatthewOfficerAug 01 '24Proposed Sale279.8416,1724,525,555Aug 01 04:28 PM
FILLER LINDADirectorAug 01 '24Proposed Sale279.503,9281,097,876Aug 01 12:27 PM
Blair RainerOfficerJul 31 '24Proposed Sale280.009,0072,521,960Jul 31 04:26 PM
Ellis Brian WSenior Vice President - GCJul 25 '24Sale275.169,6002,641,53620,230Jul 26 05:03 PM
Raskas DanielSVP - Corporate DevelopmentJul 25 '24Sale270.5114,5073,924,35223,595Jul 26 05:03 PM
Zerhouni Elias A.DirectorJul 15 '24Option Exercise52.563,289172,87037,483Jul 16 05:01 PM
SCHWIETERS JOHN TDirectorJul 15 '24Option Exercise52.563,289172,87019,808Jul 16 05:00 PM
King WilliamSVP, Strategic DevelopmentMay 15 '24Option Exercise50.3712,623635,82155,208May 17 05:10 PM
Blair RainerPresident & CEOMay 16 '24Sale265.009,0052,386,325106,990May 17 05:08 PM
Blair RainerPresident & CEOMay 14 '24Option Exercise59.9119,0851,143,435135,080May 15 05:00 PM
Blair RainerPresident & CEOMay 14 '24Sale255.0019,0854,866,675115,995May 15 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerMay 10 '24Option Exercise61.2525,1741,541,79445,338May 13 05:01 PM
McGrew MatthewEVP & Chief Financial OfficerMay 10 '24Sale253.0546,37711,735,85629,407May 13 05:01 PM
SPOON ALAN GDirectorMay 02 '24Option Exercise52.563,289172,870116,910May 03 05:03 PM
SPOON ALAN GDirectorMay 02 '24Sale243.58708172,455116,202May 03 05:03 PM